Strategies for the development of vaccines conferring broad-spectrum protection

International Journal of Medical Microbiology

Volumn 298, Issue 5-6, 2008, Pages 379-395

  Nagy, Gábor ^a   Emody, Levente ^a   Pál, Tibor ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Broad coverage; Cross protection; Multivalent vaccines; Rational attenuation; Vaccination; Virulence regulation

Indexed keywords

ADHESIN; CYTOTOXIC NECROTIZING FACTOR 1; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; INACTIVATED VACCINE; LIPOPOLYSACCHARIDE; O ANTIGEN; ORAL POLIOMYELITIS VACCINE; PNEUMOCOCCUS VACCINE; VACCINE; VIRULENCE FACTOR;

ANTIGEN EXPRESSION; BACTERIAL VIRULENCE; CROSS PROTECTION; ENTEROBACTERIACEAE; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNE RESPONSE; KLEBSIELLA PNEUMONIAE; NONHUMAN; SALMONELLA ENTERICA; SALMONELLA TYPHI; SALMONELLA TYPHIMURIUM; SEROTYPE; SHIGELLA FLEXNERI; SHORT SURVEY; STREPTOCOCCUS PNEUMONIAE; UROPATHOGENIC ESCHERICHIA COLI; VACCINATION; YERSINIA ENTEROCOLITICA;

ANTIGENS, BACTERIAL; ANTIGENS, VIRAL; BACTERIAL VACCINES; CROSS REACTIONS; HUMANS; SEROTYPING; VIRAL VACCINES;

EID: 44449119362     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2008.01.012     Document Type: Short Survey

References (152)

1. Adu-Bobie J., Capecchi B., Serruto D., Rappuoli R., and Pizza M. Two years into reverse vaccinology. Vaccine 21 (2003) 605-610
2. Agnello D., Herve C.A., Lavaux A., Darniot M., Guillon P., Charpilienne A., and Pothier P. Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice. J. Virol. 80 (2006) 3823-3832
3. Altboum Z., Barry E.M., Losonsky G., Galen J.E., and Levine M.M. Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection. Infect. Immun. 69 (2001) 3150-3158
4. Andres I., Rodriguez-Diaz J., Buesa J., and Zueco J. Yeast expression of the VP8* fragment of the rotavirus spike protein and its use as immunogen in mice. Biotechnol. Bioeng. 93 (2006) 89-98
5. Angel J., Franco M.A., and Greenberg H.B. Rotavirus vaccines: recent developments and future considerations. Nat. Rev. Microbiol. 5 (2007) 529-539
6. Bailey M.J., Hughes C., and Koronakis V. Increased distal gene transcription by the elongation factor RfaH, a specialized homologue of NusG. Mol. Microbiol. 22 (1996) 729-737
7. Bailey M.J., Hughes C., and Koronakis V. RfaH and the ops element, components of a novel system controlling bacterial transcription elongation. Mol. Microbiol. 26 (1997) 845-851
8. Balbontin R., Rowley G., Pucciarelli M.G., Lopez-Garrido J., Wormstone Y., Lucchini S., Garcia-Del Portillo F., Hinton J.C., and Casadesus J. DNA adenine methylation regulates virulence gene expression in Salmonella enterica serovar Typhimurium. J. Bacteriol. 188 (2006) 8160-8168
9. Barzu S., Fontaine A., Sansonetti P., and Phalipon A. Induction of a local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate: implications for use of IpaC as a protein carrier. Infect. Immun. 64 (1996) 1190-1196
10. Belogurov G.A., Vassylyeva M.N., Svetlov V., Klyuyev S., Grishin N.V., Vassylyev D.G., and Artsimovitch I. Structural basis for converting a general transcription factor into an operon-specific virulence regulator. Mol. Cell 26 (2007) 117-129
11. Bertolotti-Ciarlet A., Ciarlet M., Crawford S.E., Conner M.E., and Estes M.K. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine 21 (2003) 3885-3900
12. Beutin L., Manning P.A., Achtman M., and Willetts N. sfrA and sfrB products of Escherichia coli K-12 are transcriptional control factors. J. Bacteriol. 145 (1981) 840-844
13. Bonacorsi S., and Bingen E. Molecular epidemiology of Escherichia coli causing neonatal meningitis. Int. J. Med. Microbiol. 295 (2005) 373-381
14. Brodeur B.R., Boyer M., Charlebois I., Hamel J., Couture F., Rioux C.R., and Martin D. Identification of group B streptococcal Sip protein, which elicits cross-protective immunity. Infect. Immun. 68 (2000) 5610-5618
15. Buttery J.P., and Kirkwood C. Rotavirus vaccines in developed countries. Curr. Opin. Infect. Dis. 20 (2007) 253-258
16. Carter H.D., Svetlov V., and Artsimovitch I. Highly divergent RfaH orthologs from pathogenic proteobacteria can substitute for Escherichia coli RfaH both in vivo and in vitro. J. Bacteriol. 186 (2004) 2829-2840
17. Carter J.A., Blondel C.J., Zaldivar M., Alvarez S.A., Marolda C.L., Valvano M.A., and Contreras I. O-antigen modal chain length in Shigella flexneri 2a is growth-regulated through RfaH-mediated transcriptional control of the wzy gene. Microbiology 153 (2007) 3499-3507
18. Chakrabarti S., and Sinha A.K. Antibody response to outer membrane proteins in Shigella dysenteriae type 1 infection with special reference to appearance of murine antibodies. Indian J. Med. Res. 104 (1996) 142-147
19. Chen R.T., and Orenstein W.A. Epidemiologic methods in immunization programs. Epidemiol. Rev. 18 (1996) 99-117
20. Clarke B.R., Pearce R., and Roberts I.S. Genetic organization of the Escherichia coli K10 capsule gene cluster: identification and characterization of two conserved regions in group III capsule gene clusters encoding polysaccharide transport functions. J. Bacteriol. 181 (1999) 2279-2285
21. Clemens J.D., Sack D.A., Harris J.R., Chakraborty J., Neogy P.K., Stanton B., Huda N., Khan M.U., Kay B.A., and Khan M.R. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J. Infect. Dis. 158 (1988) 372-377
22. Clifford G.M., Smith J.S., Plummer M., Munoz N., and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Brit. J. Cancer 88 (2003) 63-73
23. Cochi S.L., Broome C.V., and Hightower A.W. Immunization of US children with Hemophilus influenzae type b polysaccharide vaccine. A cost-effectiveness model of strategy assessment. JAMA 253 (1985) 521-529
24. Cohen D., Ashkenazi S., Green M.S., Gdalevich M., Robin G., Slepon R., Yavzori M., Orr N., Block C., Ashkenazi I., Shemer J., Taylor D.N., Hale T.L., Sadoff J.C., Pavliakova D., Schneerson R., and Robbins J.B. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 349 (1997) 155-159
25. Cohen S., Mendelson I., Altboum Z., Kobiler D., Elhanany E., Bino T., Leitner M., Inbar I., Rosenberg H., Gozes Y., Barak R., Fisher M., Kronman C., Velan B., and Shafferman A. Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect. Immun. 68 (2000) 4549-4558
26. Cox J.T. Epidemiology and natural history of HPV. J. Fam. Pract. Suppl. (2006) 3-9
27. Creeger E.S., Schulte T., and Rothfield L.I. Regulation of membrane glycosyltransferases by the sfrB and rfaH genes of Escherichia coli and Salmonella typhimurium. J. Biol. Chem. 259 (1984) 3064-3069
28. Cutts F.T., Zaman S.M., Enwere G., Jaffar S., Levine O.S., Okoko J.B., Oluwalana C., Vaughan A., Obaro S.K., Leach A., McAdam K.P., Biney E., Saaka M., Onwuchekwa U., Yallop F., Pierce N.F., Greenwood B.M., and Adegbola R.A. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365 (2005) 1139-1146
29. Czarny A., Witkowska D., and Mulczyk M. Studies on nonspecific protection induced with OMP of Shigella flexneri and other genera of Enterobacteriaceae. Arch. Immunol. Ther. Exp. (Warsz.) 38 (1990) 353-357
30. Daudel D., Weidinger G., and Spreng S. Use of attenuated bacteria as delivery vectors for DNA vaccines. Expert Rev. Vaccines 6 (2007) 97-110
31. Davies M.N., and Flower D.R. Harnessing bioinformatics to discover new vaccines. Drug Discov. Today 12 (2007) 389-395
32. Davis C.E., Ziegler E.J., and Arnold K.F. Neutralization of meningococcal endotoxin by antibody to core glycolipid. J. Exp. Med. 147 (1978) 1007-1017
33. Dean-Nystrom E.A., Gansheroff L.J., Mills M., Moon H.W., and O'Brien A.D. Vaccination of pregnant dams with intimin(O157) protects suckling piglets from Escherichia coli O157:H7 infection. Infect. Immun. 70 (2002) 2414-2418
34. De Filette M., Min J.W., Birkett A., Lyons K., Schultz B., Tonkyro A., Resch S., and Fiers W. Universal influenza A vaccine: optimization of M2-based constructs. Virology 337 (2005) 149-161
35. De Filette M., Ramne A., Birkett A., Lycke N., Lowenadler B., Min J.W., Saelens X., and Fiers W. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24 (2006) 544-551
36. De Groot A.S., and Berzofsky J.A. From genome to vaccine - new immunoinformatics tools for vaccine design. Methods 34 (2004) 425-428
37. De Groot A.S., and Moise L. New tools, new approaches and new ideas for vaccine development. Expert Rev. Vaccines 6 (2007) 125-127
38. DeMaria Jr. A., Johns M.A., Berberich H., and McCabe W.R. Immunization with rough mutants of Salmonella minnesota: initial studies in human subjects. J. Infect. Dis. 158 (1988) 301-311
39. Diemert D.J. Prevention and self-treatment of traveler's diarrhea. Clin. Microbiol. Rev. 19 (2006) 583-594
40. Di Padova F.E., Brade H., Barclay G.R., Poxton I.R., Liehl E., Schuetze E., Kocher H.P., Ramsay G., Schreier M.H., and McClelland D.B. A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides. Infect. Immun. 61 (1993) 3863-3872
41. Dueger E.L., House J.K., Heithoff D.M., and Mahan M.J. Salmonella DNA adenine methylase mutants elicit protective immune responses to homologous and heterologous serovars in chickens. Infect. Immun. 69 (2001) 7950-7954
42. Echarti C., Hirschel B., Boulnois G.J., Varley J.M., Waldvogel F., and Timmis K.N. Cloning and analysis of the K1 capsule biosynthesis genes of Escherichia coli: lack of homology with Neisseria meningitidis group B DNA sequences. Infect. Immun. 41 (1983) 54-60
43. El Adhami W., Kyd J.M., Bastin D.A., and Cripps A.W. Characterization of the gene encoding a 26-kilodalton protein (OMP26) from nontypeable Haemophilus influenzae and immune responses to the recombinant protein. Infect. Immun. 67 (1999) 1935-1942
44. Ernst R.K., Guina T., and Miller S.I. Salmonella typhimurium outer membrane remodeling: role in resistance to host innate immunity. Microbes Infect. 3 (2001) 1327-1334
45. Eskola J., Kilpi T., Palmu A., Jokinen J., Haapakoski J., Herva E., Takala A., Kayhty H., Karma P., Kohberger R., Siber G., and Makela P.H. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344 (2001) 403-409
46. Estes M.K., Ball J.M., Guerrero R.A., Opekun A.R., Gilger M.A., Pacheco S.S., and Graham D.Y. Norwalk virus vaccines: challenges and progress. J. Infect. Dis. 181 Suppl. 2 (2000) S367-S373
47. Etz H., Minh D.B., Henics T., Dryla A., Winkler B., Triska C., Boyd A.P., Söllner J., Schmidt W., von Ahsen U., Buschle M., Gill S.R., Kolonay J., Khalak H., Fraser C.M., von Gabain A., Nagy E., and Meinke A. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc. Natl. Acad. Sci. USA 99 (2002) 6573-6578
48. Feikin D.R., and Klugman K.P. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin. Infect. Dis. 35 (2002) 547-555
49. Fiers W., De Filette M., Birkett A., Neirynck S., and Min J.W. A "universal" human influenza A vaccine. Virus Res. 103 (2004) 173-176
50. Finne J., Leinonen M., and Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2 (1983) 355-357
51. Francis Jr. T., Korns R.F., Voight R.B., Boisen M., Hemphill F.M., Napier J.A., and Tolchinsky E. An evaluation of the 1954 poliomyelitis vaccine trials. Am. J. Public Health Nations Health 45 (1955) 1-63
52. Franco M.A., Angel J., and Greenberg H.B. Immunity and correlates of protection for rotavirus vaccines. Vaccine 24 (2006) 2718-2731
53. Galan J.E., and Curtiss III R. Virulence and vaccine potential of phoP mutants of Salmonella typhimurium. Microb. Pathog. 6 (1989) 433-443
54. Gebriel A.M., Subramaniam G., and Sekaran S.D. The detection and characterization of pathogenic Leptospira and the use of OMPs as potential antigens and immunogens. Trop. Biomed. 23 (2006) 194-207
55. Gonzalez B.E., Hulten K.G., Lamberth L., Kaplan S.L., and Mason Jr. E.O. Streptococcus pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine. Pediatr. Infect. Dis. J. 25 (2006) 301-305
56. Gupta S., and Maiden M.C. Exploring the evolution of diversity in pathogen populations. Trends Microbiol. 9 (2001) 181-185
57. Guzman C.A., Borsutzky S., Griot-Wenk M., Metcalfe I.C., Pearman J., Collioud A., Favre D., and Dietrich G. Vaccines against typhoid fever. Vaccine 24 (2006) 3804-3811
58. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., Jenkins D., Schuind A., Costa Clemens S.A., and Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
59. Hausdorff W.P., Siber G., and Paradiso P.R. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet 357 (2001) 950-952
60. Hausdorff W.P., Feikin D.R., and Klugman K.P. Epidemiological differences among pneumococcal serotypes. Lancet Infect. Dis. 5 (2005) 83-93
61. Heaton P.M., Goveia M.G., Miller J.M., Offit P., and Clark H.F. Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. J. Infect. Dis. 192 Suppl. 1 (2005) S17-S21
62. Heithoff D.M., Sinsheimer R.L., Low D.A., and Mahan M.J. An essential role for DNA adenine methylation in bacterial virulence. Science 284 (1999) 967-970
63. Heithoff D.M., Enioutina E.Y., Daynes R.A., Sinsheimer R.L., Low D.A., and Mahan M.J. Salmonella DNA adenine methylase mutants confer cross-protective immunity. Infect. Immun. 69 (2001) 6725-6730
64. Hellman J., Zanzot E.M., Loiselle P.M., Amato S.F., Black K.M., Ge Y., Kurnick J.T., and Warren H.S. Antiserum against Escherichia coli J5 contains antibodies reactive with outer membrane proteins of heterologous Gram-negative bacteria. J. Infect. Dis. 176 (1997) 1260-1268
65. Henrichsen J. Typing of Streptococcus pneumoniae: past, present, and future. Am. J. Med. 107 (1999) 50S-54S
66. Hobbs M., and Reeves P.R. The JUMPstart sequence: a 39 bp element common to several polysaccharide gene clusters. Mol. Microbiol. 12 (1994) 855-856
67. Hohmann E.L., Oletta C.A., Killeen K.P., and Miller S.I. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J. Infect. Dis. 173 (1996) 1408-1414
68. Huang S.S., Platt R., Rifas-Shiman S.L., Pelton S.I., Goldmann D., and Finkelstein J.A. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 116 (2005) e408-e413
69. Hughey P.G., Compans R.W., Zebedee S.L., and Lamb R.A. Expression of the influenza A virus M2 protein is restricted to apical surfaces of polarized epithelial cells. J. Virol. 66 (1992) 5542-5552
70. Karch H., Tarr P.I., and Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int. J. Med. Microbiol. 295 (2005) 405-418
71. Klee S.R., Tzschaschel B.D., Singh M., Falt I., Lindberg A.A., Timmis K.N., and Guzman C.A. Construction and characterization of genetically-marked bivalent anti-Shigella dysenteriae 1 and anti-Shigella flexneri Y live vaccine candidates. Microb. Pathog. 22 (1997) 363-376
72. Koprowski H., Levine M.M., Anderson R.J., Losonsky G., Pizza M., and Barry E.M. Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli. Infect. Immun. 68 (2000) 4884-4892
73. Landraud L., Gibert M., Popoff M.R., Boquet P., and Gauthier M. Expression of cnf1 by Escherichia coli J96 involves a large upstream DNA region including the hlyCABD operon, and is regulated by the RfaH protein. Mol. Microbiol. 47 (2003) 1653-1667
74. Leeds J.A., and Welch R.A. RfaH enhances elongation of Escherichia coli hlyCABD mRNA. J. Bacteriol. 178 (1996) 1850-1857
75. Lindberg A.A., and Hellerqvist C.G. Rough mutants of Salmonella typhimurium: immunochemical and structural analysis of lipopolysaccharides from rfaH mutants. J. Gen. Microbiol. 116 (1980) 25-32
76. Liniger M., Zuniga A., and Naim H.Y. Use of viral vectors for the development of vaccines. Expert Rev. Vaccines 6 (2007) 255-266
77. Lipsitch M. Interpreting results from trials of pneumococcal conjugate vaccines: a statistical test for detecting vaccine-induced increases in carriage of nonvaccine serotypes. Am. J. Epidemiol. 154 (2001) 85-92
78. Low D.A., Weyand N.J., and Mahan M.J. Roles of DNA adenine methylation in regulating bacterial gene expression and virulence. Infect. Immun. 69 (2001) 7197-7204
79. Maione D., Margarit I., Rinaudo C.D., Masignani V., Mora M., Scarselli M., Tettelin H., Brettoni C., Iacobini E.T., Rosini R., D'Agostino N., Miorin L., Buccato S., Mariani M., Galli G., Nogarotto R., Nardi D.V., Vegni F., Fraser C., Mancuso G., Teti G., Madoff L.C., Paoletti L.C., Rappuoli R., Kasper D.L., Telford J.L., and Grandi G. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 309 (2005) 148-150
80. Makela P.H., Sibakov M., Herva E., Henrichsen J., Luotonen J., Timonen M., Leinonen M., Koskela M., Pukander J., Pontynen S., Gronroos P., and Karma P. Pneumococcal vaccine and otitis media. Lancet 2 (1980) 547-551
81. Malley R., Lipsitch M., Stack A., Saladino R., Fleisher G., Pelton S., Thompson C., Briles D., and Anderson P. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect. Immun. 69 (2001) 4870-4873
82. Malley R., Morse S.C., Leite L.C., Areas A.P., Ho P.L., Kubrusly F.S., Almeida I.C., and Anderson P. Multiserotype protection of mice against pneumococcal colonization of the nasopharynx and middle ear by killed nonencapsulated cells given intranasally with a nontoxic adjuvant. Infect. Immun. 72 (2004) 4290-4292
83. Marolda C.L., and Valvano M.A. Promoter region of the Escherichia coli O7-specific lipopolysaccharide gene cluster: structural and functional characterization of an upstream untranslated mRNA sequence. J. Bacteriol. 180 (1998) 3070-3079
84. Martin C., Williams A., Hernandez-Pando R., Cardona P.J., Gormley E., Bordat Y., Soto C.Y., Clark S.O., Hatch G.J., Aguilar D., Ausina V., and Gicquel B. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 24 (2006) 3408-3419
85. Mayr U.B., Walcher P., Azimpour C., Riedmann E., Haller C., and Lubitz W. Bacterial ghosts as antigen delivery vehicles. Adv. Drug Deliv. Rev. 57 (2005) 1381-1391
86. McCabe W.R. Immunization with R mutants of S. minnesota. I. Protection against challenge with heterologous Gram-negative bacilli. J. Immunol. 108 (1972) 601-610
87. McCabe W.R., Bruins S.C., Craven D.E., and Johns M. Cross-reactive antigens: their potential for immunization-induced immunity to Gram-negative bacteria. J. Infect. Dis. 136 Suppl. (1977) S161-S166
88. Mel D.M., Arsic B.L., Nikolic B.D., and Radovanic M.L. Studies on vaccination against bacillary dysentery. 4. Oral immunization with live monotypic and combined vaccines. Bull. World Health Organ. 39 (1968) 375-380
89. Miller S.I., Kukral A.M., and Mekalanos J.J. A two-component regulatory system (phoP phoQ) controls Salmonella typhimurium virulence. Proc. Natl. Acad. Sci. USA 86 (1989) 5054-5058
90. Monsieurs P., De Keersmaecker S., Navarre W.W., Bader M.W., De Smet F., McClelland M., Fang F.C., De Moor B., Vanderleyden J., and Marchal K. Comparison of the PhoPQ regulon in Escherichia coli and Salmonella typhimurium. J. Mol. Evol. 60 (2005) 462-474
91. Montigiani S., Falugi F., Scarselli M., Finco O., Petracca R., Galli G., Mariani M., Manetti R., Agnusdei M., Cevenini R., Donati M., Nogarotto R., Norais N., Garaguso I., Nuti S., Saletti G., Rosa D., Ratti G., and Grandi G. Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect. Immun. 70 (2002) 368-379
92. Morgan E., Campbell J.D., Rowe S.C., Bispham J., Stevens M.P., Bowen A.J., Barrow P.A., Maskell D.J., and Wallis T.S. Identification of host-specific colonization factors of Salmonella enterica serovar Typhimurium. Mol. Microbiol. 54 (2004) 994-1010
93. Mullan N.A., Newsome P.M., Cunnington P.G., Palmer G.H., and Wilson M.E. Protection against Gram-negative infections with antiserum to lipid A from Salmonella minnesota R595. Infect. Immun. 10 (1974) 1195-1201
94. Müller-Loennies S., Brade L., and Brade H. Neutralizing and cross-reactive antibodies against enterobacterial lipopolysaccharide. Int. J. Med. Microbiol. 297 (2007) 321-340
95. Nagy G., Dobrindt U., Schneider G., Khan A.S., Hacker J., and Emody L. Loss of regulatory protein RfaH attenuates virulence of uropathogenic Escherichia coli. Infect. Immun. 70 (2002) 4406-4413
96. Nagy G., Dobrindt U., Hacker J., and Emody L. Oral immunization with an RfaH mutant elicits protection against salmonellosis in mice. Infect. Immun. 72 (2004) 4297-4301
97. Nagy G., Danino V., Dobrindt U., Pallen M., Chaudhuri R., Emody L., Hinton J.C., and Hacker J. Down-regulation of key virulence factors makes the Salmonella enterica serovar Typhimurium rfaH mutant a promising live-attenuated vaccine candidate. Infect. Immun. 74 (2006) 5914-5925
98. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., and Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5 (1999) 1157-1163
99. Newcombe J., Eales-Reynolds L.J., Wootton L., Gorringe A.R., Funnell S.G., Taylor S.C., and McFadden J.J. Infection with an avirulent phoP mutant of Neisseria meningitidis confers broad cross-reactive immunity. Infect. Immun. 72 (2004) 338-344
100. Newcombe J., Jeynes J.C., Mendoza E., Hinds J., Marsden G.L., Stabler R.A., Marti M., and McFadden J.J. Phenotypic and transcriptional characterization of the meningococcal PhoPQ system, a magnesium-sensing two-component regulatory system that controls genes involved in remodeling the meningococcal cell surface. J. Bacteriol. 187 (2005) 4967-4975
101. Noriega F.R., Liao F.M., Maneval D.R., Ren S., Formal S.B., and Levine M.M. Strategy for cross-protection among Shigella flexneri serotypes. Infect. Immun. 67 (1999) 782-788
102. Oberhelman R.A., Kopecko D.J., Salazar-Lindo E., Gotuzzo E., Buysse J.M., Venkatesan M.M., Yi A., Fernandez-Prada C., Guzman M., and Leon-Barua R. Prospective study of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides. Infect. Immun. 59 (1991) 2341-2350
103. Oosterhuis-Kafeja F., Beutels P., and Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine 25 (2007) 2194-2212
104. Pagliusi S.R., and Teresa A.M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23 (2004) 569-578
105. Palese P. Making better influenza virus vaccines?. Emerg. Infect. Dis. 12 (2006) 61-65
106. Peltola H., Kilpi T., and Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet 340 (1992) 592-594
107. Phalipon A., and Sansonetti P.J. Shigellosis: innate mechanisms of inflammatory destruction of the intestinal epithelium, adaptive immune response, and vaccine development. Crit. Rev. Immunol. 23 (2003) 371-401
108. Phalipon A., Costachel C., Grandjean C., Thuizat A., Guerreiro C., Tanguy M., Nato F., Vulliez-Le Normand B., Belot F., Wright K., Marcel-Peyre V., Sansonetti P.J., and Mulard L.A. Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine. J. Immunol. 176 (2006) 1686-1694
109. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Arico B., Comanducci M., Jennings G.T., Baldi L., Bartolini E., Capecchi B., Galeotti C.L., Luzzi E., Manetti R., Marchetti E., Mora M., Nuti S., Ratti G., Santini L., Savino S., Scarselli M., Storni E., Zuo P., Broeker M., Hundt E., Knapp B., Blair E., Mason T., Tettelin H., Hood D.W., Jeffries A.C., Saunders N.J., Granoff D.M., Venter J.C., Moxon E.R., Grandi G., and Rappuoli R. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287 (2000) 1816-1820
110. Poolman J.T. Pneumococcal vaccine development. Expert Rev. Vaccines 3 (2004) 597-604
111. Rahman M., Matthijnssens J., Yang X., Delbeke T., Arijs I., Taniguchi K., Iturriza-Gomara M., Iftekharuddin N., Azim T., and Van Ranst M. Evolutionary history and global spread of the emerging g12 human rotaviruses. J. Virol. 81 (2007) 2382-2390
112. Rahn A., Drummelsmith J., and Whitfield C. Conserved organization in the cps gene clusters for expression of Escherichia coli group 1 K antigens: relationship to the colanic acid biosynthesis locus and the cps genes from Klebsiella pneumoniae. J. Bacteriol. 181 (1999) 2307-2313
113. Rao V., Dhar N., and Tyagi A.K. Modulation of host immune responses by overexpression of immunodominant antigens of Mycobacterium tuberculosis in bacille Calmette-Guerin. Scand. J. Immunol. 58 (2003) 449-461
114. Robbins J.B., Austrian R., Lee C.J., Rastogi S.C., Schiffman G., Henrichsen J., Makela P.H., Broome C.V., Facklam R.R., and Tiesjema R.H. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J. Infect. Dis. 148 (1983) 1136-1159
115. Robertson H.E., Acker M.S., Dillenberg H.O., Woodrow R., Wilson R.J., Ing W.K., and MacLeod D.R. Community-wide use of a "balanced" trivalent oral poliovirus vaccine (Sabin). A report of the 1961 trial at Prince Albert, Saskatchewan. Can. J. Public Health 53 (1962) 179-191
116. Roche A.M., King S.J., and Weiser J.N. Live attenuated Streptococcus pneumoniae strains induce serotype-independent mucosal and systemic protection in mice. Infect. Immun. 75 (2007) 2469-2475
117. Roden R.B., Yutzy W.H., Fallon R., Inglis S., Lowy D.R., and Schiller J.T. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270 (2000) 254-257
118. Rojas G., Saldias S., Bittner M., Zaldivar M., and Contreras I. The rfaH gene, which affects lipopolysaccharide synthesis in Salmonella enterica serovar Typhi, is differentially expressed during the bacterial growth phase. FEMS Microbiol. Lett. 204 (2001) 123-128
119. Ross B.C., Czajkowski L., Hocking D., Margetts M., Webb E., Rothel L., Patterson M., Agius C., Camuglia S., Reynolds E., Littlejohn T., Gaeta B., Ng A., Kuczek E.S., Mattick J.S., Gearing D., and Barr I.G. Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. Vaccine 19 (2001) 4135-4142
120. Ruffolo C.G., and Adler B. Cloning, sequencing, expression, and protective capacity of the oma87 gene encoding the Pasteurella multocida 87-kilodalton outer membrane antigen. Infect. Immun. 64 (1996) 3161-3167
121. Ruggeberg J.U., and Pollard A.J. Meningococcal vaccines. Paediatr. Drugs 6 (2004) 251-266
122. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., Cheuvart B., Espinoza F., Gillard P., Innis B.L., Cervantes Y., Linhares A.C., Lopez P., Macias-Parra M., Ortega-Barria E., Richardson V., Rivera-Medina D.M., Rivera L., Salinas B., Pavia-Ruz N., Salmeron J., Ruttimann R., Tinoco J.C., Rubio P., Nunez E., Guerrero M.L., Yarzabal J.P., Damaso S., Tornieporth N., Saez-Llorens X., Vergara R.F., Vesikari T., Bouckenooghe A., Clemens R., De Vos B., and O'Ryan M. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N. Engl. J. Med. 354 (2006) 11-22
123. Russo T.A., Beanan J.M., Olson R., Genagon S.A., Macdonald U., Cope J.J., Davidson B.A., Johnston B., and Johnson J.R. A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate. Vaccine 25 (2007) 3859-3870
124. Rustam T., McClean S., Newcombe J., McFadden J., and Eales-Reynolds L.J. Reduced toxicity of lipo-oligosaccharide from a phoP mutant of Neisseria meningitidis: an in vitro demonstration. J. Endotoxin Res. 12 (2006) 39-46
125. Samajdar S., Varghese V., Barman P., Ghosh S., Mitra U., Dutta P., Bhattacharya S.K., Narasimham M.V., Panda P., Krishnan T., Kobayashi N., and Naik T.N. Changing pattern of human group A rotaviruses: emergence of G12 as an important pathogen among children in eastern India. J. Clin. Virol. 36 (2006) 183-188
126. Santos N., and Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev. Med. Virol. 15 (2005) 29-56
127. Schiff D.E., Wass C.A., Cryz Jr. S.J., Cross A.S., and Kim K.S. Estimation of protective levels of anti-O-specific lipopolysaccharide immunoglobulin G antibody against experimental Escherichia coli infection. Infect. Immun. 61 (1993) 975-980
128. Schuijffel D.F., Van Empel P.C., Pennings A.M., Van Putten J.P., and Nuijten P.J. Successful selection of cross-protective vaccine candidates for Ornithobacterium rhinotracheale infection. Infect. Immun. 73 (2005) 6812-6821
129. Schuijffel D.F., Van Empel P.C., Segers R.P., Van Putten J.P., and Nuijten P.J. Vaccine potential of recombinant Ornithobacterium rhinotracheale antigens. Vaccine 24 (2006) 1858-1867
130. Selman S., Hayes D., Perin L.A., and Hayes W.S. Pneumococcal conjugate vaccine for young children. Manag. Care 9 (2000) 49-52, 54, 56-57
131. Serushago B.A., Mitsuyama M., Handa T., Koga T., and Nomoto K. Role of antibodies against outer-membrane proteins in murine resistance to infection with encapsulated Klebsiella pneumoniae. J. Gen. Microbiol. 135 (1989) 2259-2268
132. Shapiro E.D., and Ward J.I. The epidemiology and prevention of disease caused by Haemophilus influenzae type b. Epidemiol. Rev. 13 (1991) 113-142
133. Singleton R.J., Hennessy T.W., Bulkow L.R., Hammitt L.L., Zulz T., Hurlburt D.A., Butler J.C., Rudolph K., and Parkinson A. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297 (2007) 1784-1792
134. Soncini F.C., Garcia V.E., Solomon F., and Groisman E.A. Molecular basis of the magnesium deprivation response in Salmonella typhimurium: identification of PhoP-regulated genes. J. Bacteriol. 178 (1996) 5092-5099
135. Spier R.E. On the need for, and the delivery of, cross-protective vaccines. Vaccine 23 (2005) 2027-2029
136. Stevens M.P., Clarke B.R., and Roberts I.S. Regulation of the Escherichia coli K5 capsule gene cluster by transcription antitermination. Mol. Microbiol. 24 (1997) 1001-1012
137. Stock A.M., Robinson V.L., and Goudreau P.N. Two-component signal transduction. Annu. Rev. Biochem. 69 (2000) 183-215
138. Tabaraie B., Sharma B.K., Sharma P.R., Sehgal R., and Ganguly N.K. Evaluation of Salmonella porins as a broad spectrum vaccine candidate. Microbiol. Immunol. 38 (1994) 553-559
139. Tai S.S. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit. Rev. Microbiol. 32 (2006) 139-153
140. Taylor D.N., Trofa A.C., Sadoff J., Chu C., Bryla D., Shiloach J., Cohen D., Ashkenazi S., Lerman Y., and Egan W. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect. Immun. 61 (1993) 3678-3687
141. Teele D.W., Klein J.O., Bratton L., Fisch G.R., Mathieu O.R., Porter P.J., Starobin S.G., Tarlin L.D., and Younes R.P. Use of pneumococcal vaccine for prevention of recurrent acute otitis media in infants in Boston. The Greater Boston Collaborative Otitis Media Study Group. Rev. Infect. Dis. 3 Suppl. (1981) S113-S118
142. van der Woude M.W., and Bäumler A.J. Phase and antigenic variation in bacteria. Clin. Microbiol. Rev. 17 (2004) 581-611 table
143. Vemulapalli R., He Y., Cravero S., Sriranganathan N., Boyle S.M., and Schurig G.G. Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51. Infect. Immun. 68 (2000) 3286-3289
144. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., Dallas M.J., Heyse J.F., Goveia M.G., Black S.B., Shinefield H.R., Christie C.D., Ylitalo S., Itzler R.F., Coia M.L., Onorato M.T., Adeyi B.A., Marshall G.S., Gothefors L., Campens D., Karvonen A., Watt J.P., O'Brien K.L., DiNubile M.J., Clark H.F., Boslego J.W., Offit P.A., and Heaton P.M. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med. 354 (2006) 23-33
145. Wang L., Jensen S., Hallman R., and Reeves P.R. Expression of the O antigen gene cluster is regulated by RfaH through the JUMPstart sequence. FEMS Microbiol. Lett. 165 (1998) 201-206
146. Wang L.Y., and Frasch C.E. Development of a Neisseria meningitidis group B serotype 2b protein vaccine and evaluation in a mouse model. Infect. Immun. 46 (1984) 408-414
147. Weiser J.N., and Tuomanen E.I. Disease-oriented approach to the discovery of novel vaccines. In: Bloom B., and Lambert P.-H. (Eds). The Vaccine Book (2003), Academic Press, New York 139-147
148. Wilfert C.M. Epidemiology of Haemophilus influenzae type b infections. Pediatrics 85 (1990) 631-635
149. Wion D., and Casadesus J. N6-methyl-adenine: an epigenetic signal for DNA-protein interactions. Nat. Rev. Microbiol. 4 (2006) 183-192
150. Wizemann T.M., Heinrichs J.H., Adamou J.E., Erwin A.L., Kunsch C., Choi G.H., Barash S.C., Rosen C.A., Masure H.R., Tuomanen E., Gayle A., Brewah Y.A., Walsh W., Barren P., Lathigra R., Hanson M., Langermann S., Johnson S., and Koenig S. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect. Immun. 69 (2001) 1593-1598
151. Zaidi T.S., Priebe G.P., and Pier G.B. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection. Infect. Immun. 74 (2006) 975-983
152. Zimmer S.M., and Stephens D.S. Serogroup B meningococcal vaccines. Curr. Opin. Investig. Drugs 7 (2006) 733-739